Tests a new MRI scan to assess liver scarring and portal hypertension
Studies a non-invasive MRI scan to estimate liver pressure in people with cirrhosis.
Plain-language title generated from the registry record
Registry title: 3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension
Key facts
- Where
- Shenyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced chronic liver disease from any cause who are due to have a liver pressure measurement (HVPG) and had a 3D-MRE scan within one month before.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed advanced chronic liver disease (ACLD), from any liver disease cause.
- Earlier treatment
- Must not have taken nonselective β-blockers (NSBB) between the MRE scan and the HVPG measurement.
Main reasons for not taking part
- Cancer in or outside the liver, or large liver or spleen lesions that affect the MRE result
- Reasons that rule out an MR scan or HVPG measurement
- Earlier liver or spleen surgery that affects the MRE result
- Invalid or unreliable HVPG or MRE results
- Blocked or widened bile ducts seen on the MR images
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05475015, who can take part
Where in China
- Shengjing HospitalShenyang, ChinaContact: Yifei Huang, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shengjing Hospital
- Trial code
- NCT05475015
- Record updated
- 9 February 2026
- Original description
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.Read full original descriptionShow less
Three-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension (CHESS2206): A Prospective Multicenter Study
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.